Medtide

Medtide ROA

The Return on Assets (ROA) of Medtide (3880.HK) as of Oct 22, 2026 is 11.99 %. In the previous year, Return on Assets (ROA) was 5.05 % — a change of 137.65% (higher).

ROA

11.99 %

YoY

137.65%

Last updated:

In 2025, Medtide's return on assets (ROA) was 11.99 %, a 137.65% increase from the 5.05 % ROA in the previous year.

The Medtide ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2021
7.04 CNY
Jan 1, 2022
4.36 CNY
Jan 1, 2023
3.74 CNY
Jan 1, 2024
5.05 CNY
Jan 1, 2025
11.99 CNY
The Medtide ROA history
YEARROAYoY
11.99 %+137.65%
5.05 %+35.04%
3.74 %-14.22%
4.36 %-38.11%
7.04 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medtide Stock analysis

What does Medtide do? Medtide, Inc. generates revenue through peptide-focused contract research, development, and manufacturing services. The company offers CRO services for peptide new chemical entity (NCE) discovery and synthesis, alongside CDMO services covering peptide chemistry, manufacturing, and control (CMC) development and commercial production. Its primary clients are pharmaceutical companies seeking active pharmaceutical ingredients (APIs) rather than finished drug products, with services delivered across domestic and overseas markets. The firm's revenue streams are derived from these specialized peptide-related R&D and manufacturing contracts. Medtide's business model centers on providing comprehensive peptide development and manufacturing solutions, including CMC filing support for clients. The company's services target the API segment of the pharmaceutical industry, focusing on peptide-based drug development rather than final drug formulations. This specialization allows Medtide to serve clients requiring high-quality peptide synthesis and manufacturing capabilities for their drug development pipelines. The company's revenue is generated through direct contracts with pharmaceutical firms for peptide-related services, including discovery synthesis, CMC development, and commercial manufacturing. These services are delivered to clients operating in both domestic and international markets, with the firm emphasizing its expertise in peptide chemistry and manufacturing processes. Medtide's business model relies on its ability to provide end-to-end peptide development and manufacturing solutions to pharmaceutical clients. Medtide is one of the most popular companies on Eulerpool.

ROA Details

Understanding Medtide's Return on Assets (ROA)

Medtide's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Medtide's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Medtide's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Medtide’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Medtide stock

Return on Assets (ROA) of Medtide is 11.99 % in 2025.

Return on Assets (ROA) of Medtide changed from 5.05 % to 11.99 %, representing a 137.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Medtide since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Medtide with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Medtide

All Key Metrics — Medtide